Kidney Cancer Journal 79 temic agents for RCC. The now well-known immune modulatory and antigen presenting properties of SAbR, which has not been elaborated and is beyond the scope of this review, may synergize with the approved and upcoming immunotherapies for RCC. While much is known about the local control, the impact of SAbR on PFS and eventually on extending patient survival is not known yet and careful design of prospective trials is clearly needed in this setting. With greater application of SAbR, the focus needs to be maintained on careful patient selection for the technique to be safely and effectively implemented and outcomes optimized, including long-term survival. References 1. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate risk prostate cancer. J Clin Oncol. 2011;29(15):2020-6. Epub 2011/04/06. doi: 10.1200/JCO.2010.31.4377. PubMed PMID: 21464418; PMCID: 3138546. 2. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-6. 3. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, Meier R, Wang J, Kupelian P, Steinberg M, Katz A. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiotherapy and Oncology. 2013. doi: 10.1016/j.radonc.2013.08.030. PubMed PMID: 24060175. 4. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8(1):118. doi: 10.1186/1748-717X-8-118. PubMed PMID: 23668632; PMCID: 3674983. 5. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947-52. 6. Berber B, Sanabria JR, Braun K, Yao M, Ellis RJ, Kunos CA, Sohn J, Machtay M, Teh BS, Huang Z, Mayr NA, Lo SS. Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer. Expert Review of Anticancer Therapy. 2013;13(4):481-7. 7. Tao C, Yang LX. Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiation therapy. Anticancer Research. 2012;32(2):649-55. 8. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475. doi: 10.1186/1471-2407-10-475. PubMed PMID: 20813065; PMCID: 2940809. 9. Bondiau PY, Courdi A, Bahadoran P, Chamorey E, Queille-Roussel C, Lallement M, Birtwisle-Peyrottes I, Chapellier C, Pacquelet-Cheli S, Ferrero JM. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. International Journal of Radiation Oncology, Biology, Physics. 2013;85 (5):1193-9. 10. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. American Journal of Clinical Oncology. 2007;30 (6):637-44. 11. Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forquer JA, Papiez L, McGarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD. Stereotactic body radiation therapy for oligometastases. Expert Review of Anticancer Therapy. 2009;9(5):621-35. 12. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD. Stereotactic body radiation therapy: a novel treatment modality. Nature Reviews Clinical Oncology. 2010;7(1):44-54. 13. Bianco AI, The BS, Amato RJ. Role of radiation therapy in the management of renal cell carcinoma. Cancers. 2011;3:4010-4023. 14. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34:251-266. 15.Ning S, Trisler K, Wessels BW, et al. Radiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80:(Suppl) 2519- 25288. 16.Walsh L, Stanfield JL, Cho LC, et al. Efficacy of ablative high-dose-per fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;50:795-800. 17. Shuto T, Matsunaga S, Suenaga J, Inomori S, Fujino H. Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. Journal of Neuro-Oncology. 2010;98(2):169-75. 18. Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine. 2007;32(2):193-9. 19. Gerszten PC, Burton SA, Ozhasoglu C, Vogel WJ, Welch WC, Baar J, Friedland DM. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. Journal of neurosurgery Spine. 2005;3(4):288-95. 20. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, Zatcky J, Zelefsky MJ, Fuks Z. High-dose, single-fraction imageguided intensity-modulated radiotherapy for metastatic spinal lesions. International Journal of Radiation Oncology, Biology, Physics. 2008; 71(2):484-90. 21. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2010;76(4):1185-92. 22. Ranck MC, Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, Hahn OM, Weichselbaum RR, Salama JK. Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 2012. Epub 2012/08/08. doi:10. 1097/COC.0b013e31825d52b2. PubMed PMID: 22868242. 23. Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Naslund I, Pisa P, Svedman C. Extracranial stereotactic radiotherapy for primary and meitastatic renal cell carcinoma. Radiotherapy and Oncology. 2005;77(1):88-95. 24. Adler JR, Chang SD, Murphy MJ, et al. The Cyberknife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg. 1997;69:124- 128. 25. Siva S, Pham D, Gill S, et al. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110: E77377-E743. 26. Lo CH, Huang WY, Chao HL, et al. Novel application of stereotactic ablative radiotherapy using Cyberkife for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: initial clinical experiences. Oncol Lett. 2014;8:355-360. 27. Sun MRM, Brook A, Powell MF, et al. Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors. Am J Roent. 2016;544-553. 28. McBride SM, Warner AA, Kaplan ID. A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma. Int J Rad Oncol Biol Phys. 2013;87:S84. 29. Ponsky L, Lo SS, Zhang Y, et al. Phase I dose-escalation study of stereotactic body radiotherapy (SAbR) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol.2015;117:183-187. 30. Lo SS, Loblaw A, Chang EL, Mayr NA, Teh BS, Huang Z, et al. Emerging applications of stereotactic body radiotherapy. Future Oncol. 2014;10: 1299–310. 31. Staehler M, Bader M, Schlenker B, et al. Single fraction radiosurgery for the treatment of renal tumors. J Urol. 2015;193:771-775. 32. ClinicalTrials.gov.NCT02141919 33. Focus ablative Stereotactic tadiosurgery for cancers of the kidney— a phase II clinical trial. TROG trial 15.03 on Australian Cancer Trials website. 34. Hannan R, Margulis V, Chun SG, et al. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biology & Therapy. 2015;16:65-661.
30114GA
To see the actual publication please follow the link above